Aizen Therapeutics
Aizen is an AI-driven biotechnology company pioneering Mirror Peptides, a novel class of biologic medicines. They develop synthetic, fully D-amino acid peptides that offer enhanced stability and reduced immunogenicity, aiming to improve therapeutic safety and efficacy. Their proprietary AI platform, DaX™, enables rapid design of these peptides for various indications, including neurological disorders, oncology, and genetic diseases.
Industries
Nr. of Employees
small (1-50)
Aizen Therapeutics
Products
Structure‑based AI platform for de novo D‑peptide design
An AI‑driven, structure‑based protein design platform that generates de novo D‑amino acid peptide candidates using generative models, computational binding evaluation, and multi‑objective optimization to prioritize properties such as specificity, half‑life, and solubility.
Therapeutic discovery pipeline (discovery → IND‑enabling → Phase 1)
Internal therapeutic programs progressing from discovery through IND‑enabling activities toward Phase 1, with programmatic focus areas in neurological disorders, oncology, and genetic diseases.
Structure‑based AI platform for de novo D‑peptide design
An AI‑driven, structure‑based protein design platform that generates de novo D‑amino acid peptide candidates using generative models, computational binding evaluation, and multi‑objective optimization to prioritize properties such as specificity, half‑life, and solubility.
Therapeutic discovery pipeline (discovery → IND‑enabling → Phase 1)
Internal therapeutic programs progressing from discovery through IND‑enabling activities toward Phase 1, with programmatic focus areas in neurological disorders, oncology, and genetic diseases.
Services
Collaborative discovery and development partnerships
Collaborative research and partnership opportunities to apply AI‑driven peptide design and preclinical development capabilities to partner targets and programs.
Collaborative discovery and development partnerships
Collaborative research and partnership opportunities to apply AI‑driven peptide design and preclinical development capabilities to partner targets and programs.
Expertise Areas
- D‑amino acid peptide therapeutics
- AI‑driven protein design
- Structure‑based de novo design
- Peptide targeting and delivery
Key Technologies
- Generative AI (guided diffusion)
- Computational binding prediction
- Structure‑based protein/peptide design
- GPU‑accelerated compute